Tivic Health Reports 39% Revenue Decline and Increased Operating Expenses in Q2 2025

Tivic Health Systems, Inc. reported its financial results for the second quarter of 2025, revealing a significant decline in revenue and an increase in operating expenses compared to the same period in 2024. For the three months ended June 30, 2025, the company generated $86,000 in revenue, a decrease of 39% from $140,000 in the prior year. For the first half of 2025, total revenue was $156,000, down 67% from $474,000 in the same period last year. The decline in revenue was attributed to a 41% drop in unit sales, which management linked to a 57% reduction in advertising spend as resources were redirected towards advancing the company's TLR5 program.

The company's operating expenses for the second quarter increased to $1.99 million, up from $1.30 million in the same quarter of 2024. This rise was driven by higher research and development costs, which surged to $655,000 from $302,000, reflecting the company's focus on its biopharmaceutical initiatives, particularly the TLR5 agonist Entolimod. General and administrative expenses also rose, totaling $907,000 compared to $787,000 in the previous year. As a result, Tivic reported a net loss of $1.93 million for the quarter, compared to a loss of $1.27 million in the same quarter of 2024.

In terms of strategic developments, Tivic Health made significant strides in its biopharmaceutical efforts, including the acquisition of an exclusive worldwide license for Entolimod from Statera Biopharma in February 2025. This license includes options for additional indications, which Tivic is actively pursuing. The company also reported a reverse stock split effective March 7, 2025, aimed at improving its stock price and compliance with listing requirements. As of June 30, 2025, Tivic had 965,899 shares of common stock outstanding, a significant increase from 556,902 shares at the end of 2024.

Operationally, the company has been focusing on its ClearUP product, which treats sinus pain and congestion. However, sales have been impacted by reduced marketing efforts, and management indicated plans to explore alternative monetization strategies or potentially exit the consumer business altogether. The company’s cash and cash equivalents stood at $1.18 million as of June 30, 2025, down from $2.00 million at the end of 2024, raising concerns about its ability to sustain operations without additional funding.

Looking ahead, Tivic Health's management expressed uncertainty regarding its ability to continue as a going concern, citing the need for additional capital to fund ongoing operations and development activities. The company plans to focus on advancing its biopharmaceutical candidates and may seek further financing through equity or debt offerings. The outlook remains cautious as Tivic navigates the challenges of reduced revenue and increased operational costs while striving to bring its new products to market.